Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma. - Wikidata - awgldk - TriplyDB

Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma.

Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma.

http://www.wikidata.org/entity/Q37609768

about

Commentary on Pharmacometrics for Immunotherapy.Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma.Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.

P2860

Q39082975-64716983-2CF2-46CF-946C-CB526DFFD036 Q45367967-A1D0F518-4729-420F-85BA-836406E75B48 Q50638216-9868125B-C887-4D43-8973-B4B9A86C9846

P2860

Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma.

http://www.wikidata.org/entity/Q37609768

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Quantitative Characterization ...... tients With Advanced Melanoma.

@en

Quantitative Characterization ...... tients With Advanced Melanoma.

@nl

type

label

Quantitative Characterization ...... tients With Advanced Melanoma.

@en

Quantitative Characterization ...... tients With Advanced Melanoma.

@nl

prefLabel

Quantitative Characterization ...... tients With Advanced Melanoma.

@en

Quantitative Characterization ...... tients With Advanced Melanoma.

@nl

P1433

Q37609768-D1A651B6-A112-4A74-9D8A-F1985ACA80C7

P1476

Q37609768-1E71D116-294A-48AD-BEC1-5E46CF81AB10

P2093

Q37609768-0F07EC6F-5188-4CD0-A678-DD9DA12E4296

Q37609768-18F95EF2-EF9E-4063-84C6-C5AAB5897BBB

Q37609768-234A7DF2-A17D-474E-8147-01918C4DC9E0

Q37609768-51971D17-BA20-4C8E-AC9E-B8443432AB16

Q37609768-578B1ABB-FF6B-4C66-A623-099A73F24B81

Q37609768-93AAFB33-D19B-4939-8284-B3A3CC12DD26

Q37609768-B837E0E3-1D45-4E89-8212-2545914112CD

Q37609768-C9FBAC3A-FA4F-43CC-B3FD-62E60B6EA8BF

Q37609768-F55C81EB-1A4A-4208-B4DB-43A25D6663D9

P2860

Q37609768-021E524C-D91B-42AB-A6AA-73DBDAF386E0

Q37609768-0C17CB1F-D8CC-48B7-87B2-F7336501B737

Q37609768-0C3FA6D1-1B82-432D-AF85-41DB13129497

Q37609768-0D29F481-9CA8-4F1C-90DB-38122FFF142C

Q37609768-1FC3E679-F207-4FF6-9B7A-5735193803BE

Q37609768-1FF36D0B-F3DB-47DB-BFD6-B4FFC348345F

Q37609768-22242D2E-2507-4388-BEAD-147915FAD863

Q37609768-26FEC75F-693A-4CF7-9C68-2C4972809289

Q37609768-3450E12B-7BA0-4024-9A38-A7901CBE94F4

Q37609768-3C2FD832-9231-415A-A9C0-58BF977A8EC2

P304

Q37609768-48EAC38B-C3A1-4E65-96A8-EA73915533FF

P31

Q37609768-41BBD931-6730-49E7-9E2B-007F53E6F543

P356

Q37609768-524C4E87-C3EA-4B46-989C-1B8A67F3CD9A

P433

Q37609768-816EB811-EF1C-48C7-A4B3-FBD5471BF7B2

P478

Q37609768-78635F9E-021C-4E02-8B0E-7310B8702597

P577

Q37609768-4FEBE71F-0832-4AA1-BAF2-943AB9FA9AAF

P698

Q37609768-2A71C057-F084-49FF-B085-10840086A085

P921

Q37609768-124AC30D-8E80-49CB-AA11-6F4D86F13406

P932

Q37609768-680D90D2-CC23-4976-A219-597C770FDCD7

P356

P1433

CPT: pharmacometrics & systems pharmacology

P1476

Quantitative Characterization ...... tients With Advanced Melanoma.

@en

P2093

A Roy

http://www.w3.org/2001/XMLSchema#string

A Yang

http://www.w3.org/2001/XMLSchema#string

B Lestini

http://www.w3.org/2001/XMLSchema#string

G Bajaj

http://www.w3.org/2001/XMLSchema#string

J-S Park

http://www.w3.org/2001/XMLSchema#string

M Gupta

http://www.w3.org/2001/XMLSchema#string

S Agrawal

http://www.w3.org/2001/XMLSchema#string

X Wang

http://www.w3.org/2001/XMLSchema#string

Y Feng

http://www.w3.org/2001/XMLSchema#string

P2860

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

PD-1 and its ligands in tolerance and immunity

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Nivolumab in previously untreated melanoma without BRAF mutation

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

P304

40-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PSP4.12133

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28019090

http://www.w3.org/2001/XMLSchema#string

P921

P932

5270290

http://www.w3.org/2001/XMLSchema#string